Target Validation Information
TTD ID	T09694
Target Name	Glucagon-like peptide 1 (GLP-1:7-37)
Type of Target	Literature-reported
Drug Potency against Target	Albiglutide	Drug Info	EC50 = 1.5 nM	[1]
Action against Disease Model	Lixisenatide	Drug Info	Lixisenatide protected Ins-1 cells (a rat-derived beta-cell line) from both lipid- and cytokine-induced apoptosis. More importantly, Lixisenatide also prevented lipotoxicity-induced insulin depletion in h uMan islets and preserved insulin production, storage and pancreatic beta-cell function in vitro. In animal models of diabetes, Lixisenatide improved basal blood glucose and HbA(1c) with a rapid onset and sustained duration of action, and prevented the deterioration of pancreatic responsiveness and glucose homeostasis. Lixisenatide also delayed gastric emptying and reduced food intake.	[2]
References
REF 1	Medicinal Chemistry of Incretin Mimetics and DPP-4 Inhibitors. ChemMedChem. 2010 Feb 1;5(2):179-85.
REF 2	Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas. Cancer Res. 2011 Apr 1;71(7):2643-53.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.